CBUS earnings date and last-quarter result: next report 2026-08-13, last quarter beat, P/E -1.01. Updated 2026-07-23.
Cibus (CBUS) Research Hub
Cibus (CBUS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.395 USD (-1.06%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.01, market cap 0.08B. This hub links to the full technical, earnings and options research available for CBUS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.395 USD (-1.06%) |
| 52-week range | 1.25 USD – 2.43 USD |
| Trend regime | Range |
| 14-day RSI | 34.2 (Bearish) |
| Trailing P/E | -1.01 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for CBUS
Covered Call on CBUS: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CBUS: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CBUS: how it works, illustrative setup around the real 1.4 USD price, max profit/loss, breakeven and when to use it. Educational.
CBUS technical analysis: range, last 1.395 USD, RSI 34.2, 52w range 1.25 USD–2.43 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CBUS in?
Cibus (CBUS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CBUS in an uptrend or downtrend?
As of 2026-10-26, CBUS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CBUS's trailing P/E ratio?
CBUS's trailing P/E is -1.01, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does CBUS next report earnings?
CBUS is next scheduled to report earnings on 2026-08-13.